ABSTRACT Lithium, a common drug for the treatment of bipolar disorder (BD), requires chronic administration to prevent recurrences of the illness. The necessity for long-term treatment

suggests that changes in genes expression are involved in the mechanism of its action. We studied effects of lithium on gene expression in lymphoblasts from BD patients, all excellent

responders to lithium prophylaxis. Gene expression was analyzed using cDNA arrays that included a total of 2400 cDNAs. We found that chronic lithium treatment at a therapeutically relevant

concentration decreased the expression of seven genes in lymphoblasts from lithium responders. Five of these candidate lithium-regulated genes, including alpha1B-adrenoceptor (_α_1B-AR),

bipolar subjects and healthy control subjects at baseline, prior to lithium administration, we found that _α_1B-AR gene expression was higher in bipolar subjects than in healthy control

subjects. Our findings indicate that _α_1B-AR may play an important role in the mechanism of action of lithium treatment. SIMILAR CONTENT BEING VIEWED BY OTHERS TRANSCRIPTIONAL ANALYSIS OF

SODIUM VALPROATE IN A SEROTONERGIC CELL LINE REVEALS GENE REGULATION THROUGH BOTH HDAC INHIBITION-DEPENDENT AND INDEPENDENT MECHANISMS Article 01 March 2021 IMMUNOGLOBULIN GENES EXPRESSED IN

LYMPHOBLASTOID CELL LINES DISCERN AND PREDICT LITHIUM RESPONSE IN BIPOLAR DISORDER PATIENTS Article Open access 24 July 2023 A LONGITUDINAL STUDY OF GENE EXPRESSION IN FIRST-EPISODE

SCHIZOPHRENIA; EXPLORING RELAPSE MECHANISMS BY CO-EXPRESSION ANALYSIS IN PERIPHERAL BLOOD Article Open access 19 October 2021 INTRODUCTION Lithium is the most commonly prescribed treatment

for bipolar disorder (BD). Prophylactic treatment with lithium prevents recurrences of depression and mania in a substantial proportion of patients with this disorder (Davis et al, 1999).

Much research has shown that lithium regulates components of signal transduction pathways and their downstream gene transcription factors, an indication that changes in gene expression are

likely to underlie the mechanism of action of the treatment (Manji and Zarate, 2002; Bezchlibnyk and Young, 2002). Lithium-induced changes in gene expression have been documented in both

cultured cells and animal models (Kalasapudi et al, 1990; Williams and Jope, 1994; Manji et al, 1995a, 1995b). Several studies have demonstrated that lithium alters the expression of the

early response gene c-_fos_ through a protein kinase C-mediated mechanism (Divish et al, 1991; Manji and Lenox, 1994). For example, incubation of PC-12 cells for 16 h with lithium

significantly potentiates c-_fos_ expression induced by the muscarinic agonist carbachol. Lithium pretreatment in these cells also potentiates c-_fos_ expression in response to phorbol

esters, which are known to directly activate protein kinase C (Divish et al, 1991). More recently, chronic lithium treatment has been found to induce the gene expression of antiapoptotic

factor bcl-2 in the frontal cortex from rat (Chen et al, 1999; Chen and Chuang, 1999). Nonetheless, the evidence thus far accumulated on lithium-induced changes in gene expression still

provides an incomplete picture of the underlying mechanism of this drug. Therefore, isolation of other genes regulated by lithium is very important, particularly if these genes are found to

be involved in the development of BD. Simultaneous large-scale analysis of gene expression has recently been enabled by the development of DNA array analysis (Marcotte et al, 2001; Nguyen et

al, 2002). Recently, Bosetti et al (2002) described gene expression changes in rat brain in animals treated with lithium for 7 and 42 days respectively. The genes showing a change in

expression were related to a variety of cell functions and all were downregulated by lithium. In this study we used the cDNA array analysis to investigate the effect of lithium on gene

expression in lymphoblasts from patients with BD who have shown response to lithium treatment to further characterize the targets of this drug. MATERIALS AND METHODS SUBJECTS The

investigations were carried out on a sample of 12 patients diagnosed with BD and in eight healthy control subjects. The demographic data for both groups are given in Table 1. The patients

were diagnosed using Research Diagnostic Criteria, RDC (Spitzer et al, 1978), following Schedule for Affective Disorders and Schizophrenia—Lifetime version, SADS-L (Endicott and Spitzer,

1978), interviews. All patients also met DSM-IV criteria for BD type I or II. In addition to diagnosis of BD, they all had to meet criteria of full response to lithium prophylaxis. Patients

were considered as excellent lithium responders when the following criteria A, B and C were met: * A.: Diagnosis of primary episodic BD based on the SADS-L (lifetime version) interview and

Research Diagnostic Criteria (RDC). * B.: High recurrence risk (B1 or B2 or B3). * B1:: Five or more episodes prior to lithium. * B2:: Four episodes prior to lithium; of these two or more

during the 2 years preceding lithium. * B3:: Three episodes prior to lithium, plus one more within 12 months after lithium discontinuation. * C.: Unequivocal lithium response (C1 and C2 and

C3). * C1:: No recurrence requiring additional biological intervention (ECT, antidepressants, neuroleptics) during the entire observation time on lithium monotherapy. * C2:: Minimum period

of observation of 3 years. * C3:: Average plasma lithium concentration over 0.6 mEq/l. The criteria for determining such response have been described in previous papers (Grof et al, 1994;

Turecki et al, 1998). The patients included in this study had 9.4±3.8 episodes of illness before the treatment and have remained well for 10.2±6.8 years on treatment with lithium alone. The

control subjects were recruited from married-in members of probands' families and were interviewed using SADS-L to exclude any persons with psychiatric disorders. For cDNA array

hybridization we selected two bipolar subjects, the confirmatory study with Northern blotting analysis based on the entire sample. The project was approved by the Research Ethics Committees

at all institutions involved. All subjects gave written informed consent to their participation in the study. CELL CULTURE AND DRUG TREATMENT B lymphocytes from patients were transformed

with Epstein–Barr virus. Transformed cells were cultured in ISCOV'S medium (GIBCO 12440-053) containing 15% of fetal bovine serum and 2 mM L-glutamine, and maintained at 37°C in the

present of 5% CO2 and 95% air in a humidified incubator. Cells from each subject were divided into two groups, and were treated with vehicle or 1 mM LiCl for 7 days. RNA PREPARATION AND CDNA

ARRAY ANALYSIS Total RNA from lymphoblasts was isolated using Trizol reagent (Gibco, MD), following the manufacturer's instruction. The concentration of RNA was determined by measuring

the OD at 260 nm and the purity was determined by the ratio of 260/280. In all, 3 μg of total RNA were subjected to electrophoresis on a denaturing 1% agarose gel to check the integrity of

the RNA (18S and 28S rRNA bands). Gene expression was analyzed using Atlas™ Human 1.2 Array I and II including 2400 cDNAs (Clontech Laboratories). In total, 5 μg of total RNA from vehicle-

and LiCl-treated cells were treated with RNase-free DNAse I (Gibco BRL) to digest contaminating genomic DNA. RNA was then reverse transcribed using moloney murine leukemia virus reverse

transcriptase in the presence of [_α_-32P]dATP and a specific CDS primer mix (supplied by Clontech). 32P-labeled cDNA probes were purified from unincorporated nucleotides and small cDNA

fragments with a CHROMA SPIN-200 column (Clontech). A set of array membranes were prehybridized at 68°C for 30 min in ExpressHyb solution with salmon sperm DNA (100 μg/ml) and hybridized at

68°C overnight in the same solution with equal amounts of cDNA probes from vehicle and lithium-treated cell, respectively. Membranes were washed three times in 2 × SSC, 1% SDS for 30 min at

68°C and twice in 0.1 SSC, 0.5% SDS for 30 min at 68°C. Membranes were exposed to a Phosphor Screen and scanned using a PhosphorImage (Molecular Dynamics, Inc., Sunnyvale, CA). NORTHERN BLOT

ANALYSIS Total RNA was run on a 1% agarose gel containing 0.66 M formaldehyde, and applied to a nylon membrane by capillary transfer (Amersham Pharmarcia) and ultraviolet-crosslinked.

Membranes were prehybridized at 68°C for 30 min in ExpressHyb hybridization buffer (CLONTECH) and hybridized at 68°C for 1 h in the same buffer with cDNA probes, according to the

manufacturer's instruction (Clontech). cDNA probes from their coding region were generated by reverse transcriptase PCR and labeled with [_α_-32P]dCTP by using a random prime labeling

method (Feinberg and Vogelstein, 1983). Membranes were then washed at room temperature for 30 min in 2 × SSC, 0.1% SDS twice and at 50°C for 30 min in 0.1 × SSC, 0.1% SDS twice. Membranes

were exposed overnight to a Phosphor Screen and scanned using PhosphorImage (Molecular Dynamics, Inc., Sunnyvale, CA). STATISTICAL ANALYSIS AtlasImage Software from Clontech (CA) was used to

determine the signal intensities for each DNA spot. The intensity of each spot was adjusted by the global intensity normalization approach. The signal intensity was normalized by adding the

values of signal for each spot over the median value of all genes on each array. Data from Northern blotting analysis were obtained by densitometric analysis of autoradiograms using

ImageQuant from Molecular Dynamics (CA). Results were expressed as percent of control. Changes in gene expression after drug treatment were expressed as the mean±SEM from separate

experiments. Statistical significance of differences between means was determined by ANOVA with one within (treatment) and one grouping (cases _vs_ controls) factors, and by nonparametric

methods using the Mann–Whitney test for between-group comparisons, and the Wilcoxon test for within-group comparisons. RESULTS EB virus-transformed B lymphocytes from lithium responders were

chronically treated with vehicle (control) or 1 mM LiCl for 1 week. cDNA probes generated from vehicle- or lithium-treated cells were hybridized with two identical Atlas™ Human 1.2 Array I

and II cDNA arrays on membranes containing in 2400 genes total, including transcription factors, ion channels, transport proteins, and receptors among others. By comparing signal intensity

between vehicle- and drug-treated cells, we identified seven lithium-regulated genes. The experiment was duplicated. To eliminate false positive results, we included only genes with (1) the

expression increased or decreased in duplicate samples; (2) signal ratios of lithium- to vehicle-treated cells of ⩾1.3; and (3) signal intensity of ⩾2000 as determined using Atlas Image

software (Clontech). As shown in Figure 1, chronic lithium treatment decreased the expression of the following seven genes: alpha1B-adrenoceptor (_α_1B-AR), acetylcholine receptor protein

alpha chain precursor (ACHR), cAMP-dependent 3′,5′-cyclic phosphodiesterase 4D (PDE4D), substance-P receptor (SPR), somatostatin receptor type 2 (SSTR2), nuclear factor kappa-B DNA binding

subunit (NF-_κ_B), and ras-related protein RAB7 (Figure 1). Northern blotting analysis was used to verify lithium-regulated gene candidates in a larger group of lithium responders (_n_=12).

Partial cDNA sequence of _α_1B-AR, ACHR, PDE4D, SPR, SSTR2, NF-_κ_B and RAB7 was used as a probe to hybridize with Northern blots containing total RNA from vehicle- and lithium-treated cells

to confirm their differential expression. Hybridization signal for RAB7 showed two bands on the gel, which have been identified as high weight molecular RAB7H and low weight molecular RAB7L

(Vitelli et al, 1996), while signal for other genes only showed single bands. We confirmed that chronic lithium treatment significantly decreased the expression of _α_1B-AR (_P_<0.01),

PDE4D (_P_<0.01), ACHR (_P_<0.01), SPR (_P_<0.05), and RAB7H (_P_<0.05) (Figure 2). We did not confirm the effect of lithium on the expression of SSTR2, NF-_κ_B, and RAB7L (data

not shown). To determine whether chronic lithium treatment has similar effect on the expression of _α_1B-AR, ACHR, PDE4D, SPR, and RAB7 in healthy controls as did in lithium responders, we

measured mRNA level of these five genes in vehicle- and lithium-treated lymphoblasts from healthy controls. The results showed that the expression of none of these genes was changed by

chronic lithium treatment in healthy controls (Figure 2). Finally, we compared the expression level of these candidate genes at baseline in lymphoblasts between bipolar subjects and healthy

control subjects. We found that while there was no difference of expression for ACHR, PDE4D, SPR, and RAB7, the gene for _α_1B-AR showed 2.5-fold higher levels of expression in bipolar

subjects compared to healthy control subjects (_P_=0.004 Figure 2). In exploratory analyses of the _α_1B-AR gene, both basal- and lithium-regulated expression did not correlate with age, age

of onset, lifetime number, and duration of depressive and manic episodes, or duration of lithium treatment (data not shown). DISCUSSION In this study, we used DNA array techniques to

analyze the expression profile of 2400 genes in lymphoblasts from lithium responder bipolar subjects after chronic lithium treatment _in vitro_. We found that chronic lithium treatment

decreased the expression of seven genes including _α_1B-AR, ACHR, PDE4D, SPR, SSTR2, NF-_κ_B, and RAB7, and that five of these seven genes, _α_1B-AR, ACHR, PDE4D, SPR, and RAB7, were

verified to be differentially expressed between vehicle- and lithium-treated cells by Northern blotting analysis. We also found that lithium decreased the expressions of these same five

genes (_α_1B-AR, ACHR, PDE4D, SPR, and RAB7) in the larger sample of lithium responders, but not in healthy controls. The most interesting finding is that _α_1B-AR gene expression is higher

in lithium responders compared with healthy control subjects. These results suggest that _α_1B-AR may play a role in the development of BD and the mechanism of action of lithium treatment.

The study also demonstrates the utility of this novel gene screening technique for the elucidation of potential candidate genes for lithium treatment. The _α_1 receptors include 1A, 1B, 1C,

and 1D subtypes and play important roles in many physiological processes, such as myocardial inotropy and chronotropy, smooth muscle contraction, motor activity and motivation (Koshimizu et

al, 2002). Stimulation of _α_1 receptors activates Gq/11 coupled phospholipase C, which hydrolyzes phosphatidylinositol 4,5-biphosphate (PIP2) to yield two second messengers, diacylglycerol,

and inositol 1,4,5-triphosphate (IP3), resulting in activation of protein kinase C and release of intracellular calcium (Sawaki et al, 1995; Parmentier et al, 2002). Many previous studies

have indicated an important role for lithium in the regulation of IP3, protein kinase C, and calcium-mediated signaling (Kurita et al, 2002; Manji et al, 1996). Lithium inhibits myo-inositol

monophosphatase, a key enzyme in inositol recycling in various tissues, which is the basis for further inositol depletion (Vadnal and Parthasarathy, 1995). It has been hypothesized that the

therapeutic effect of lithium may derive from reduced agonist-induced PI hydrolysis consequent to inositol depletion by inhibition of IMPase and reduction in PI generated second messengers

(Berridge, 1989; Berridge and Irvine, 1989; Berridge et al, 1992). This hypothesis is supported by findings of inhibition of agonist and GTP-dependent PI hydrolysis and formation of

Ins(1,4,5)P3 and/or Ins(1,3,4,5)P4 in rat brain by several groups (Whitworth and Kendall, 1988; Kennedy et al, 1989; Godfrey et al, 1989; Song and Jope, 1992). Reduction of _α_1B-AR

expression by lithium, which may further result in reduction of PI generated second messengers, suggests that lithium may regulate PI-generated second messengers by not only directly

inhibiting IMPase but also by inhibiting _α_1B-AR expression. Protein kinase C is also a target of lithium treatment. Chronic lithium treatment has been shown to decrease membrane levels of

the PKC _α_ isozyme and attenuated protein kinase C-mediated responses, such as phosphorylation of the prominent PKC substrate MARCKS in rat hippocampus (Anderson et al, 1988). In addition,

Dubovsky et al (1991) reported that lithium treatment significantly reduced resting and stimulated intracellular-free calcium in platelets of BD patients. The _α_1 receptors have also been

found to activate other signal transduction systems, such as the mitogen activated protein kinase and cAMP pathways (Michelotti et al, 2000; Piascik and Perez, 2001). Much research has

demonstrated that lithium treatment affected cAMP pathways (Bezchlibnyk and Young, 2002). Together with our finding that lithium decreased _α_1B-AR expression, this suggests that the

_α_1B-AR coupled signaling may be a pathway with multiple targets for lithium. The _α_1B-AR gene showed a significantly higher level of expression in patients compared to controls as well as

more prominent effect of lithium. This makes the gene an interesting potential target for further study in patients with BD. The receptor and its gene, however, have not been studied in

depression or BD before, and relatively little is known about their role in mood regulation. The receptor is present in a variety of tissues including high levels of expression in the

cerebral cortex. Its density can be influenced by drugs with a known effect on mood, such as reserpine or desipramine, producing up- and downregulation, respectively (Civantos Calzada and De

Artinano, 2001). _α_1B-AR is recognized to be involved in adrenoceptor-mediated active behavior, which has been used as an indicator in studies of movement and mood disorders. Stone _et al_

found that inhibition of _α_1B-AR blocked cage changing-induced gross and small movement in mice. _α_1B-AR knockout mice also showed decreased exploratory activity and fear-motivated

behavior (Knauber and Muller, 2000; Stone et al, 2001). The gene for alpha 1B receptor maps to 5q33, a region investigated with suggestive results in several linkage studies of BD (Shink et

al, 2002). It is interesting that _α_1B-AR expression is higher in bipolar patients than controls, but decreased by lithium in our study. These findings suggest that _α_1B-AR may not only be

involved in pathological development but also may be a potential target for lithium treatment. The second interesting finding in this study is the inhibitory effect of lithium on the

expression of the phosphodiesterase (PDE 4D) gene. The enzyme is important for cAMP signaling, which may be particularly relevant for the mechanism of action of lithium. Lithium has multiple

effects on cAMP signaling including inhibition of adenylyl cyclase activity—an effect that we were able to confirm in the same cell lines as those used in the present study (Sun et al,

2002). Inhibition of PDE activity has been shown to produce an antidepressant effect (Wachtel, 1983; Fujimaki et al, 2000; Zhang et al, 2002). Furthermore, an administration of a PDE4

inhibitor rolipram has been found to potentiate antidepressant-induced BDNF expression and neurogenesis in rat hippocampus (Fujimaki et al, 2000). Studies in cultured lymphoblasts from BD

patients have certain advantages: lymphocytes are easily obtained from the subjects; studies can be performed with lymphocyte from live patients from whom response to lithium treatment can

be isolated; we can perform comparison between before and after drug treatment with cultured lymphocytes in the same subject. A number of mood stabilizer and mood disorder studies have been

published on lymphocytes and platelets, but the study with lymphocytes must be interpreted with caution. The biological response may be different in EBV transformed cells when compared with

untransformed cells, and peripheral lymphocyte may not fully represent changes that occur in regionalized brain tissue. However, a number of studies have been published on transformed

lymphoblasts from BD patients, and similar biological responses as in these cells are also found in CNS (Manji et al, 1995a, 1995b; Schreiber et al, 1991; Young et al, 1991, 1993, 1994). In

conclusion, using DNA array analysis we identified a number of lithium responsive genes including _α_1B-AR in lymphocytes from BD subjects. Since previous studies have shown that lithium

regulates IP3 and protein kinase C signal transduction pathways, the regulation of _α_1B-AR expression by lithium suggests that this drug may have multiple targets for _α_1-AR and coupled

downstream signaling pathways. _α_1B-AR is highly expressed in BD subjects, but its expression is decreased by lithium treatment, indicating that _α_1B-AR may play an important role in the

action of lithium treatment. REFERENCES * Anderson SMP, Godfrey PP, Grahame-Smith DG (1988). The effects of phorbol esters and lithium on 5-HT release in rat hippocampal slices. _Br J

Pharmacol_ 93(Suppl): 96P. Google Scholar  * Berridge MJ (1989). Inositol triphosphate, calcium, lithium and cell signalling. _JAMA_ 262: 1834–1841. Article  CAS  Google Scholar  * Berridge

MJ, Downes CP, Hanley MR (1992). Lithium amplifies the agonist dependent phosphatidylinositol responses in brain and salivary glands. _Biochem J_ 206: 587–595. Article  Google Scholar  *

Berridge MJ, Irvine RF (1989). Inositol phosphates and cell signalling. _Nature_ 341: 197–205. Article  CAS  Google Scholar  * Bezchlibnyk Y, Young LT (2002). The neurobiology of bipolar

disorder: focus on signal transduction pathways and the regulation of gene expression. _Can J Psychiatry_ 47: 135–148. Article  Google Scholar  * Bosetti F, Seemann R, Bell JM, Zahorchak R,

Friedman E, Rapoport SI _et al_ (2002). Analysis of gene expression with cDNA microarrays in rat brain after 7 and 42 days of oral lithium administration. _Brain Res Bull_ 57: 205–209.

Article  CAS  Google Scholar  * Chen G, Zeng WZ, Yuan PX, Huang LD, Jiang YM, Zhao ZH _et al_ (1999). The mood-stabilizing agents lithium and valproate robustly increase the levels of the

neuroprotective protein bcl-2 in the CNS. _J Neurochem_ 72: 879–882. Article  CAS  Google Scholar  * Chen RW, Chuang DM (1999). Long term lithium treatment suppresses p53 and Bax expression

but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. _J Biol Chem_ 274: 6039–6042. Article  CAS  Google Scholar  * Civantos Calzada B, De Artinano A

(2001). Alpha-adrenoceptor subtypes. _Pharmacol Res_ 44: 195–208. Article  CAS  Google Scholar  * Davis JM, Janicak PG, Hogan DM (1999). Mood stabilizers in the prevention of recurrent

affective disorders: a meta-analysis. _Acta Psychiatr Scand_ 100: 406–417. Article  CAS  Google Scholar  * Divish MM, Sheftel G, Boyle A, Kalasapudi VD, Papolos DF (1991). Differential

effect of lithium on fos protooncogene expression mediated by receptor and postreceptor activators of protein kinase C and cyclic adenosine monophosphate: model for its antimanic action. _J

Neurosci Res_ 28: 40–48. Article  CAS  Google Scholar  * Dubovsky SL, Lee C, Christiano J (1991). Lithium decreases platelet intracellular calcium ion concentrations in bipolar patients.

_Lithium_ 2: 167–174. CAS  Google Scholar  * Endicott J, Spitzer RL (1978). A diagnostic interview: the schedule for affective disorders and schizophrenia. _Arch Gen Psychiatry_ 35: 837–844.

Article  CAS  Google Scholar  * Feinberg AP, Vogelstein B (1983). A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. _Anal Biochem_ 132: 6–13.

Article  CAS  Google Scholar  * Fujimaki K, Morinobu S, Duman RS (2000). Administration of a cAMP phosphodiesterase 4 inhibitor enhances antidepressant-induction of BDNF mRNA in rat

hippocampus. _Neuropsychopharmacology_ 22: 42–51. Article  CAS  Google Scholar  * Godfrey PP, McClue SJ, White AM, Wood AJ, Grahame-Smith DG (1989). Subacute and chronic _in vivo_ lithium

treatment inhibits agonist- and sodium fluoride-stimulated inositol phosphate production in rat cortex. _J Neurochem_ 52: 498–506. Article  CAS  Google Scholar  * Grof P, Alda M, Grof E,

Zvolsky P, Walsh M (1994). Lithium response and genetics of affective disorders. _J Affect Disord_ 32: 85–95. Article  CAS  Google Scholar  * Kalasapudi VD, Sheftel G, Divish MM, Papolos DF,

Lachman HM (1990). Lithium augments fos protooncogene expression in PC12 pheochromocytoma cells: implications for therapeutic action of lithium. _Brain Res_ 521: 47–54. Article  CAS  Google

Scholar  * Kennedy ED, Challiss RAJ, Nahorski SR (1989). Lithium reduces the accumulation of inositol polyphosphate second messengers following cholinergic stimulation of cerebral corted

slices. _J Neurochem_ 53: 1632–1635. Article  Google Scholar  * Knauber J, Muller WE (2000). Decreased exploratory activity and impaired passive avoidance behaviour in mice deficient for the

alpha(1b)-adrenoceptor. _Eur Neuropsychopharmacol_ 10: 423–427. Article  CAS  Google Scholar  * Koshimizu TA, Yamauchi J, Hirasawa A, Tanoue A, Tsujimoto G (2002). Recent progress in alpha

1-adrenoceptor pharmacology. _Biol Pharm Bull_ 25: 401–408. Article  CAS  Google Scholar  * Kurita M, Mashiko H, Rai M, Kumasaka T, Kouno S, Niwa S _et al_ (2002). Lithium chloride at a

therapeutic concentration reduces Ca2+ response in protein kinase C down-regulated human astrocytoma cells. _Eur J Pharmacol_ 442: 17–22. Article  CAS  Google Scholar  * Manji HK, Bersudsky

Y, Chen G, Belmaker RH, Potter WZ (1996). Modulation of protein kinase C isozymes and substrates by lithium: the role of myo-inositol. _Neuropsychopharmacology_ 15: 370–381. Article  CAS 

Google Scholar  * Manji HK, Chen G, Shimon H, Hsiao JK, Potter WZ, Belmaker RH (1995a). Guanine nucleotide-binding proteins in bipolar affective disorder: effects of long-term lithium

treatment. _Arch Gen Psychiatry_ 52: 135–144. Article  CAS  Google Scholar  * Manji HK, Lenox RH (1994). Long-term action of lithium: a role for transcriptional and posttranscriptional

factors regulated by protein kinase C. _Synapse_ 16: 11–28. Article  CAS  Google Scholar  * Manji HK, Potter WA, Lenox RH (1995b). Molecular targets for lithium's actions. _Arch Gen

Psychiatry_ 52: 31–543. Google Scholar  * Manji HK, Zarate CA (2002). Molecular and cellular mechanisms underlying mood stabilization in bipolar disorder: implications for the development of

improved therapeutics. _Mol Psychiatry_ 7(Suppl 1): S1–S7. Article  CAS  Google Scholar  * Marcotte ER, Srivastava LK, Quirion R (2001). DNA microarrays in neuropsychopharmacology. _Trends

Pharmacol Sci_ 22: 426–436. Article  CAS  Google Scholar  * Michelotti GA, Price DT, Schwinn DA (2000). Alpha 1-adrenergic receptor regulation: basic science and clinical implications.

_Pharmacol Ther_ 88: 281–309. Article  CAS  Google Scholar  * Nguyen DV, Arpat AB, Wang N, Carroll RJ (2002). DNA microarray experiments: biological and technological aspects. _Biometrics_

58: 701–717. Article  Google Scholar  * Parmentier JH, Ahmed A, Ruan Y, Gandhi GK, Saeed AE, Malik KU (2002). Calcium and protein kinase C (PKC)-related kinase mediate alpha 1A-adrenergic

receptor-stimulated activation of phospholipase D in rat-1 cells, independent of PKC. _J Pharmacol Exp Ther_ 303: 1206–1215. Article  CAS  Google Scholar  * Piascik MT, Perez DM (2001).

Alpha1-adrenergic receptors: new insights and directions. _J Pharmacol Exp Ther_ 298: 403–410. CAS  PubMed  Google Scholar  * Sawaki K, Baum BJ, Ambudkar IS (1995). Alpha 1-adrenergic and

m3-muscarinic receptor stimulation of phosphatidylinositol 4,5-bisphosphate-specific phospholipase C are independently mediated by G alpha q/11 in rat parotid gland membranes. _Arch Biochem

Biophys_ 316: 535–540. Article  CAS  Google Scholar  * Schreiber G, Avissar S, Danon A, Belmaker RH (1991). Hyperfunctional G proteins in mononuclear leukocytes of patients with mania. _Biol

Psychiatry_ 29: 273–280. Article  CAS  Google Scholar  * Shink E, Morissette J, Villeneuve A, Bordeleau L, Rochette D, Gagne B _et al_ (2002). Support for the presence of bipolar disorder

susceptibility loci on chromosome 5: heterogeneity in a homogeneous population in Quebec. _Prog Neuropsychopharmacol Biol Psychiatry_ 26: 1273–1277. Article  CAS  Google Scholar  * Song L,

Jope RS (1992). Chronic lithium treatment impairs phosphatidylinositol hydrolysis in membranes from rat brain regions. _J Neurochem_ 58: 2200–2206. Article  CAS  Google Scholar  * Spitzer

RL, Endicott J, Robins E (1978). Research diagnostic criteria: rationale and reliability. _Arch Gen Psychiatry_ 35: 773–782. Article  CAS  Google Scholar  * Stone EA, Lin Y, Itteera A,

Quartermain D (2001). Pharmacological evidence for the role of central alpha 1B-adrenoceptors in the motor activity and spontaneous movement of mice. _Neuropharmacology_ 40: 254–261. Article

  CAS  Google Scholar  * Sun X, Young LT, Grof P, Turecki G, Wang JF, Rouleau GA _et al_ (2002). Increase of CREB phosphorylation by lithium in B lymphocytes of bipolar disorder subjects.

_Int J Neuropsychopharmacol_ 5(Suppl 1): S59–S59. * Turecki G, Grof P, Cavazzoni P, Duffy A, Grof E, Ahrens B _et al_ (1998). Evidence for a role of phospholipase C-gamma1 in the

pathogenesis of bipolar disorder. _Mol Psychiatry_ 3: 534–538. Article  CAS  Google Scholar  * Vadnal R, Parthasarathy R (1995). Myo-inositol monophosphatase: diverse effects of lithium,

carbamazepine, and valproate. _Neuropsychopharmacology_ 12: 277–285. Article  CAS  Google Scholar  * Vitelli R, Chiariello M, Lattero D, Bruni CB, Bucci C (1996). Molecular cloning and

expression analysis of the human Rab7 GTP-ase complementary deoxyribonucleic acid. _Biochem Biophys Res Commun_ 229: 887–890. Article  CAS  Google Scholar  * Wachtel H (1983). Potential

antidepressant activity of rolipram and other selective cyclic adenosine 3′,5′-monophosphate phosphodiesterase inhibitors. _Neuropharmacology_ 22: 267–272. Article  CAS  Google Scholar  *

Whitworth P, Kendall DA (1988). Lithium selectively inhibits muscarinic receptor-stimulated inositol tetrakisphosphate accumulation in mouse cerebral cortex slices. _J Neurochem_ 51:

258–265. Article  CAS  Google Scholar  * Williams MB, Jope RS (1994). Distinctive rat brain immediate early gene responses to seiqures induced by lithium plus pilocarpine. _Mol Brain Res_

25: 80–89. Article  CAS  Google Scholar  * Young LT, Li PP, Kamble A, Siu KP, Warsh JJ (1994). Mononuclear leukocyte levels of G-proteins in depressed patients with bipolar disorder or major

depressive disorder. _Am J Psychiatry_ 151: 594–596. Article  CAS  Google Scholar  * Young LT, Li PP, Kish SJ, Siu KP, Kamble A, Hornykiewicz O _et al_ (1993). Cerebral cortex Gs_α_ protein

levels and forskolin-stimulated cyclic AMP formation are increased in bipolar affective disorder. _J Neurochem_ 61: 890–898. Article  CAS  Google Scholar  * Young LT, Li PP, Kish SJ, Siu

LP, Warsh JJ (1991). Postmortem cerebral cortex Gs alpha-subunit levels are elevated in bipolar affective disorder. _Brain Res_ 551: 323–326. Article  Google Scholar  * Zhang HT, Huang Y,

Jin SL, Frith SA, Suvarna N, Conti M _et al_ (2002). Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme.

_Neuropsychopharmacology_ 27: 587–595. CAS  PubMed  Google Scholar  Download references ACKNOWLEDGEMENTS This work is supported by a grant from Canadian Institutes of Health Research (MA and

LTY), and by Independent Investigator Award from the National Alliance for Research in Schizophrenia and Depression (MA). AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of

Psychiatry, University of Toronto, Toronto, Canada Xiujun Sun, L Trevor Young & Jun-Feng Wang * Department of Psychiatry, University of Ottawa, Ottawa, Canada Paul Grof * Department of

Psychiatry, McGill University, Montreal, Canada Gustavo Turecki * Center for Research in Neuroscience, McGill University, Montreal, Canada Guy A Rouleau * Department of Psychiatry, Dalhousie

University, Halifax, Canada Martin Alda Authors * Xiujun Sun View author publications You can also search for this author inPubMed Google Scholar * L Trevor Young View author publications

You can also search for this author inPubMed Google Scholar * Jun-Feng Wang View author publications You can also search for this author inPubMed Google Scholar * Paul Grof View author

publications You can also search for this author inPubMed Google Scholar * Gustavo Turecki View author publications You can also search for this author inPubMed Google Scholar * Guy A

Rouleau View author publications You can also search for this author inPubMed Google Scholar * Martin Alda View author publications You can also search for this author inPubMed Google

Scholar CORRESPONDING AUTHOR Correspondence to Martin Alda. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Sun, X., Young, L., Wang, JF. _et al._

Identification of Lithium-Regulated Genes in Cultured Lymphoblasts of Lithium Responsive Subjects with Bipolar Disorder. _Neuropsychopharmacol_ 29, 799–804 (2004).

https://doi.org/10.1038/sj.npp.1300383 Download citation * Received: 17 August 2003 * Revised: 02 December 2003 * Accepted: 11 December 2003 * Published: 21 January 2004 * Issue Date: 01

April 2004 * DOI: https://doi.org/10.1038/sj.npp.1300383 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable

link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative KEYWORDS * bipolar disorder * lithium * lymphoblast *

gene expression * cDNA array * alpha1B-adrenoceptor